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Abstract
This study was carried out to determine whether a short-term zinc supplementation contributes to beneficial changes in glycemic control among 
type 2 diabetic patients. Seventy-six diabetic subjects and 72 normal adults participated in this study. Subjects were divided into supplemented and 
control groups. Forty-four diabetic patients and 34 normal subjects were supplemented with 50 mg zinc daily as zinc gluconate for 4 weeks. Zinc
status was assessed from fasting plasma levels and urinary excretion. The effects of zinc supplementation on fasting blood glucose, HbA1c, insulin,
and C-peptide were measured at the beginning of the study and after 4 weeks of supplementation. The changes in glycemic control indicators were
compared between diabetic groups, classified by baseline HbA1c levels, and by diabetic duration. At baseline, the incidence of marginal zinc deficiency
in the diabetic group, as determined by plasma zinc level, was approximately twice as high as in the normal adult group. The changes of HbA1c
concentration, and fasting blood glucose following supplementation were not statistically significant in diabetic subjects. In normal subjects, a significant
decrease of HbA1c occurred only in the zinc supplemented group. No significant changes were observed for serum insulin and C-peptide in diabetic
as well as normal subjects. However, when the changes were compared by baseline HbA1c level, we found that diabetic subjects with HbA1c ≥ 
7.5% showed significantly improved levels of HbA1c and fasting glucose after Zn supplementation. While such improvement in fasting blood glucose
was significant among diabetics with shorter diabetic duration, significant levels of increase in serum insulin and C-peptide were observed in zinc
supplemented subjects with longer diabetic duration. Fasting blood glucose was significantly decreased, whereas serum insulin and C-peptide were
increased in diabetics with marginal zinc status. Therefore, we suggest that Zn supplementation for a short-term period may improve glycemic control
in diabetic patients with higher HbA1c levels and marginal zinc status.
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Introduction14)
Zinc is involved in numerous metabolic pathways as an 
cofactor for more than 300 enzymes (Rink & Kirchner, 2000). 
It also plays an important role for insulin action, carbohydrate 
and protein metabolism (Chausmer, 1998). Insulin, which 
contains a variable number of zinc atoms, are stored in β-cells 
of the pancreas and released into the portal venous system at 
the time of β-cells degranulation. Type 2 diabetes mellitus is 
a metabolic disorder with hyperglycemia as the dominant feature 
(Chausmer, 1998). 
Several investigators have shown the perturbation of zinc 
metabolism in diabetics (Golik et al., 1993; Kinlaw et al., 1983; 
Levine et al., 1983; Walter et al., 1991). It has been suggested 
that hyperzincuria and impaired absorption are major causes of 
zinc deficiency among diabetics (Cunningham et al., 1994; Heise 
et al., 1988; Kazi et al., 2008; Salgueiro et al., 2001; Walter 
et al., 1991). Clinical manifestations including delayed wound 
healing, decreased cell immunity and deterioration of taste acuity 
in this population have been also reported (Keen & Gershwin, 
1990; Kinlaw et al., 1983; Salgueiro et al., 2001). 
It was suggested that the marginal zinc deficiency may be 
related with impaired immunity and taste (Salgueiro et al., 2001). 
Hence, zinc supplementation is receiving growing attention as 
a way to improve the immune function as well as the marginal 
zinc deficiency (Anderson et al., 2001; Faure et al., 1995). 
Few studies have been conducted on the effects of zinc 
supplementation on hyperglycemia of diabetics and their results 
are inconsistent. Zinc supplementation has improved fasting 
insulin level and fasting glucose in genetically obese mice models 
(Chen  et al., 1998; Simon & Taylor, 2001). Improved fasting 
glucose levels up to 30% in patients with cirrhosis through 
supplementation of zinc for 2 months has been reported 
(Marchesini  et al., 1998). Supplementation of 30 mg zinc for 
3 months in type 2 diabetics showed a decrease in HbA1c 
concentration. Meanwhile, others reported that neither fasting 
glucose nor HbA1c levels was changed by a short-term 
supplementation with zinc for type 1 diabetics (Cunningham et 
al., 1994; de Sena et al., 2005). 
Type 2 diabetic patients are characterized by reduced secretion 
of insulin and increased insulin resistance, resulting in elevated 
blood glucose levels (Roth & Kirchgessner, 1981; Salgueiro et 
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al., 2001). It has not been clearly elucidated whether zinc 
deficiency is a consequence of hyperglycemia or, alternatively, 
whether zinc deficiency contributes to the pathogenesis of 
diabetes.
The National Health and Nutrition Examination Survey for 
Koreans conducted in 2005 showed that the prevalence of 
diabetes was 9.0% for male adults and 7.2% for female adults 
(Ministry of Health & Welfare, 2006). Previous studies indicated 
that marginal zinc deficiency is more prevalent among diabetic 
adults compared to the normal adult population (Lee et al., 2005; 
Yoon & Lee, 2007). Therefore, we intended to determine whether 
zinc supplementation for a short-term period could improve the 
levels of fasting glucose and HbA1c as well as the insulin levels 
in Korean type 2 diabetics. Moreover, this study aimed to find 
out whether the changes in glycemic control by zinc 
supplementation are associated with diabetic duration or zinc 
status. 
Materials and Methods
Subjects 
This study was conducted on 76 type 2 diabetic adults attending 
local clinics and public heath centers. Characteristics of the 
diabetic subjects have been reported elsewhere (Yoon, 2008). For 
comparison, 72 apparently healthy normal adults living in the 
same city were also recruited during the same period. Informed 
consent was obtained from each subject before the beginning 
of the study. Exclusion criteria of the subjects were pregnancy, 
lactation, consuming mineral supplements or prescribed drugs for 
diseases. The subjects were divided into zinc supplementation 
groups and control groups. Among diabetic participants, 44 
subjects took zinc supplements. Among 72 normal adults, 32 
subjects took zinc supplements. 
Methods
1) Interview questionnaire
Information on age, education levels, diabetic duration, drug 
usage, diabetic complications was interviewed by a trained 
dietitian.
2) Anthropometric Assessment 
Height, weight, circumferences of waist and hip, and body fat 
were measured from each subject. BMI (body mass index) was 
calculated with measured height and weight. Body fat content 
and percentage body fat were assessed using the Bio-electrical 
Impedance Fatness Analyzer (HBF-300, OMRON Corporation, 
Japan).
3) Biochemical Assessment 
Overnight fasting blood samples were collected either into 
evacuated heparin coated tubes or into serum tubes and were 
stored at -70℃. HbA1c, fasting blood glucose, serum insulin, and 
C-peptide were measured as the indicators of glycemic regulation 
using routine laboratory methods (Roussel et al., 2003). Plasma 
level of zinc was assessed by atomic absorption spectrometry 
(Lee et al., 2005). Urine samples for 24 hours were collected 
for one day from each subject. Urinary zinc was analyzed by 
Inductively Coupled Plasma Emission Spectroscopy (ICP) (Jobin 
Yvon, 38 plus, France). We followed the criteria for marginal 
zinc deficiency from the previous studies (King & Keen, 1994).
Zn supplementation
Selection of chemical form, dose level, and duration of zinc 
supplementation in this study were based on the reports of other 
investigators (Anderson et al., 2001; Bonham et al., 2003; 
Chandra, 1984; Roussel et al., 2003). Capsules containing 50 
mg of zinc gluconate (Labcatal, Pharmaceutical), reported as the 
safe level for supplementation for 3 months, were given to the 
diabetic and normal subjects for 4 weeks. Each subject was 
encouraged to take the supplement everyday. Compliance with 
the supplementation trial was confirmed at the end of the study. 
Subjects who reported consuming less than 80% of the total 
amounts were excluded from the data analysis.
Data Analysis 
The Statistical Analysis System (SAS) Package was used to 
analyze the relationship of glycemic control status and zinc 
supplementation. Data were presented as mean ± SD. The 
statistical significance of the differences between the diabetic and 
the normal subjects was tested by the Student’s t  test. The 
changes in glycemic indicators were compared between the two 
diabetic patients groups, first classified by baseline HbA1c levels 
(<7.5% vs ≥7.5%), then by zinc status (marginal vs normal), 
and, lastly, by diabetic duration (<4 years vs ≥4 years). 
Differences in the distribution of variables between the two 
diabetic groups were tested by the Student’s t test. The effects 
of zinc supplementation on hyperglycemia of diabetics were 
tested by paired t-test. When any variables show significant 
differences between supplemented and non-supplemented groups 
at baseline, analysis of covariance (ANCOVA) was used to 
determine the effects of supplementation. 
Results 
Baseline characteristics of the participants such as age, diabetic 
duration, are shown in Table 1. Details on the characteristics 
of the diabetic subjects were described in previous reports (Yoon, 
2008). Among diabetic participants, 44 subjects were provided 
with zinc supplement, while 32 subjects participated as the 
control group. Among the 72 normal adults, 32 subjects took Hyun-Mee Oh and Jin-Sook Yoon 285
Table 1. Baseline characteristics of the subjects
Variables
Diabetic
Supplement
(n=44)
Diabetic
Control
(n=32)
Nondiabetic
Supplement
(n=32)
Nondiabetic 
Control
(n=40)
Age  (years)   58.7±10.1  58.5±11.7  53.1±11.7  49.6±10.7
Height (cm) 161.8 ± 8.88 161.7 ± 8.38 163.0 ± 7.16 160.0 ± 7.99
Weight (kg)  63.9 ± 9.97  62.7 ± 9.61  62.7 ± 7.75  60.5 ± 9.22
Waist (cm)  84.3 ± 11.17  84.7 ± 8.87  84.5 ± 6.78  82.6 ± 8.58
Hip (cm)  97.3 ± 5.46  96.2 ± 6.52  95.4 ± 5.55  95.6 ± 5.25
WHR  0.87 ± 0.10  0.88 ± 0.06  0.89 ± 0.06  0.86 ± 0.06
BMI (kg/㎡)  24.3 ± 2.86  23.9 ± 3.09  23.6 ± 2.12  23.6 ± 2.61
Body fat (kg)  18.3 ± 4.98  17.4 ± 5.10  18.9 ± 4.47  17.3 ± 4.09
Body fat ratio (%)  27.8 ± 6.11  27.5 ± 5.89  28.6 ± 5.18 27.84 ± 5.35
Diabetic duration (yrs)  5.38 ± 3.61  6.51 ± 7.77 - -
Values  are  mean ± SD.
All average value are not significantly different among diabetic group and normal 
group.
Table 2. Effects of zinc supplementation on improvement of zinc deficiency 
Variables
Diabetic 
supplement
(n=44)
Diabetic 
Control
(n=32)
Normal 
Supplement
(n=32)
Normal 
Control
(n=40)
Marginal plasma Zn deficiency (%)
   Before 41.9 46.9 22.6 24.3
   After 22.5 43.8 19.4 19.4
Marginal urinary Zn deficiency (%)
   Before 33.3 20.0 31.9 32.3
   After 0.00 33.3 6.25 40.0
Table 3. Effects of zinc supplementation on indices of glycemic control 
Variables
Diabetic
Supplement
(n=44)
Diabetic
Control
(n=32)
Nondiabetic
Supplement
(n=32)
Nondiabetic
Control
(n=40)
HbA1C (%)
    Before  7.62 ± 1.25  7.87 ± 1.39  5.84 ± 0.41  5.69 ± 0.43
    After  7.53 ± 1.19  7.85 ± 1.63  5.67 ± 0.42  5.64 ± 0.39
  P  value NS NS  ** NS 
Fasting glucose (mg/dl)
  Before 143.0 ± 47.48 149.0 ± 66.96 91.2 ± 12.13 89.7 ± 13.73
  After 131.5 ± 44.51 135.5 ± 41.76 95.5 ± 18.99 85.9 ± 8.88
†
  P  value  0.068 NS  NS  *
Insulin (uIU/ml)
  Before     9.1 ± 4.40   13.7 ± 5.60   9.5 ± 3.38 10.0 ± 6.01
  After   11.3 ± 3.62   12.1 ± 6.91 11.3 ± 7.38   8.5 ± 3.83
†
  P  value  0.068 NS  0.087 *
C-peptide (ng/mg)
  Before   1.84 ± 0.62   2.14 ± 1.86 1.87 ± 0.77 1.80 ± 0.79
  After   2.01 ± 0.85   2.23 ± 1.60 1.99 ± 0.96 1.65 ± 0.51
  P  value  0.06 NS  NS  NS 
Values  are  mean ± SD.
*p <0.05, **p<0.01 by paired t-test between before and after treatment within group
†p<0.05  by  ANCOVA  between  supplement  and  control  group 
zinc supplement. The average age of the zinc supplemented 
diabetics was 58.7 ± 10.1 years and that of the diabetic control 
group was 58.5 ± 11.7 years. The average age of the zinc 
supplemented normal adults group was 53.1 ± 11.7 years and that 
of the diabetic control group was 49.6 ± 10.7 years. There were 
no significant differences in baseline physical characteristics such 
as age, height, weight, body mass index (BMI), circumferences 
of waist and hip, or body fat (%) between the diabetic and the 
non-diabetic adults groups. All of these variables were not 
significantly different between the supplemented and the control 
group in diabetic or non-diabetic subjects. Diabetic duration was 
5.38 ± 3.61 years for the diabetic supplemented group, 6.51 ±
7.77 years for the diabetic control group. All the physical 
characteristics were similar between subgroups of the subjects 
classified by diabetic duration.
Table 2 shows the incidence of marginal zinc deficiency at 
baseline by plasma zinc level and urinary excretion. In the 
diabetic group, more than 40% of the subjects had marginal zinc 
deficiency by plasma zinc level. By contrast, the incidence of 
marginal zinc deficiency was 22.6% in the normal supplemented, 
and 24.3% in the normal control adults. After 4 weeks of zinc 
supplementation, incidence of marginal zinc deficiency decreased 
to 22.5% in the diabetic supplement group. When the incidence 
of zinc deficiency was evaluated by urinary zinc level, 33.3% 
of the diabetic supplement group, and 20% of the diabetic control 
group were diagnosed to have marginal zinc deficiency at 
baseline. More than 30% of normal adults were found to have 
marginal zinc deficiency by urinary zinc excretion.
Table 3 compares the baseline results of HbA1c, fasting blood 
glucose, insulin, and C-peptide, which are possible indicators of 
glycemic control and insulin resistance, in diabetic and 
non-diabetic subjects. All of these variables at baseline were not 
significantly different between the supplemented and the control 
groups in diabetic or non-diabetic subjects. The fasting blood 
glucose and HbA1c in the diabetic group were significantly higher 
than the values of the normal group. However, there were no 
significant differences in insulin and C-peptide levels between 
the two groups. Serum levels of insulin and C-peptide in diabetic 
subjects were within normal ranges (insulin : 2∼25 uIU/mL and 
C-peptide : 0.48∼3.30 ng/mL). The average HbA1c of diabetics 
was higher than the normal range (4∼6%), however, it did not 
belong to the level of action suggested for the treatment (>8.0%) 
(Palumbo, 2001). 
The representative long term indicator, HbA1c did not change 
by 4 weeks zinc supplementation as is shown in Table 3. While 
HbA1c of the diabetic group slightly decreased from 7.62% to 
7.53% following zinc supplementation, without statistical 
significance, no changes occurred in diabetic control groups. By 
contrast, a significant decrease of HbA1c was observed for zinc 
supplemented normal adults after 4 weeks of supplementation. 
While the fasting plasma glucose level decreased from 143.1 
mg/dL to 131.5 mg/dL (p=0.068) in diabetic patients, serum 
levels of insulin as well as C-peptide were slightly increased 
after zinc supplementation (p=0.068, p=0.06).
When the effect of zinc supplementation on glycemic control 
was further analyzed by the baseline HbA1c  level of the diabetic 
subjects (HbA1c<7.5% vs HbA1c≥7.5%) as shown in Table 4, 
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Table 4. Effects of Zn supplementation on indices of glycemic control by HbA1c
level
Variables
Diabetic Supplement Diabetic Control
HbA1c HbA1c
7.5%  ≤
(n=22)
< 7.5%
(n=22)
7.5%  ≤
(n=18)
< 7.5%
(n=14)
HbA1c (%)
   Before  8.57 ± 1.03  6.67 ± 0.52
§§§   8.77 ± 1.16  6.71 ± 0.49
§§§
   After  8.30 ± 1.18  6.79 ± 0.60
†   8.78 ± 1.55  6.65 ± 0.63
  P-value * 0.069 NS NS
Glucose (mg/dl)
   Before 169.7 ± 49.47 116.4 ± 26.02
§§§  177.5 ± 75.87 112.3 ± 24.27
§§
   After 150.7 ± 46.89 113.1 ± 33.83 153.94 ± 40.75 112.0 ± 30.33
   P-value * NS NS NS
Insulin (uIU/ml)
   Before   9.5 ± 5.64   8.7 ± 2.73   12.1 ± 10.66  13.7 ± 5.60
   After  11.7 ± 0.08  10.8 ± 3.15   10.3 ± 4.95 14.48 ± 8.44
   P-value 0.095 *** NS NS
C-peptide (ng/mg)
   Before  2.01 ± 0.75  1.67 ± 0.42   1.80 ± 1.16  2.56 ± 2.48
   After  2.23 ± 0.92  1.80 ± 0.75   1.91 ± 0.96  2.64 ± 2.14
   P-value 0.079 NS NS NS
Values  are  mean ± SD.
*p <0.05, ** p<0.01, *** p<0.001 by paired t-test between before and after treatment 
within  group
†p<0.05  by  ANCOVA  between  supplement  and  control  group 
§ p<0.05, 
§§ p<0.01   
§§§ p<0.001  by  student  t-  test
Table 5. Effects of Zn supplementation on indices of glycemic control by 
diabetic duration 
Variables
Diabetic Supplement Diabetic Control
Diabetic duration Diabetic duration
4 years ≤
(n=24)
< 4 years 
(n=13)
4 years ≤
(n=9)
< 4 years 
(n=12)
 HbA1c (%)
  Before  7.90 ± 1.17  7.30 ± 1.30  8.26 ± 1.10  7.72 ± 1.50
  After  7.69 ± 1.19  7.34 ± 1.20  8.16 ± 0.78  7.73 ± 1.87
  P-value 0.076 NS NS NS
 Fasting glucose (mg/dl)
  Before 145.4 ± 46.34 140.3 ± 49.87 177.4 ± 84.76 137.9 ± 56.98
  After 133.6 ± 46.90 129.1 ± 42.67 152.4 ± 37.85 129.0 ± 42.12
  P-value NS * NS NS
 Insulin (uIU/ml)
  Before   8.6 ± 2.79   9.7 ± 5.80  13.8 ± 3.68  12.8 ± 6.50
  After  11.9 ± 3.20  10.6 ± 4.02  10.1 ± 4.60 12.92 ± 7.57
  Significance *** NS NS NS
 C-peptide (ng/mg)
  Before  1.89 ± 0.65  1.78 ± 0.59  1.37 ± 0.58  2.44 ± 2.11
  After  2.12 ± 0.78  1.88 ± 0.93  1.38 ± 0.65  2.56 ± 1.74
  P-value * NS NS NS
Values  are  mean ± SD.
*p <0.05, ** p<0.01, *** p<0.001 by paired t-test between before and after treatment 
within  group
Table 6. Effects of Zn supplementation on indices of glycemic control by plasma
Zn status
Variables
Diabetic Supplement Diabetic Control
Plasma Zn Plasma Zn
Marginal
(n=18)
Normal
(n=25)
Marginal
(n=15)
Normal
(n=17)
HbA1c (%)
  Before  7.54 ± 1.08  7.76 ± 1.34  8.03 ± 1.58  7.73 ± 1.23
  After  7.39 ± 1.08  7.70 ± 1.25  8.06 ± 1.91  7.67 ± 1.37
  P-value NS NS NS NS
Fasting glucose (mg/dl)
  Before 126.6 ± 38.2 157.4 ± 49.4
§ 161.3 ± 79.2 138.2 ± 54.2
  After 112.2 ± 40.5 147.7 ± 42.1 143.5 ± 42.2 128.7 ± 41.4
  P-value * NS  NS  NS
Insulin (uIU/ml)
  Before   9.4 ± 2.55   8.9 ± 5.47  11.8 ± 4.43  13.4 ± 11.2
  After  11.3 ± 2.88  11.4 ± 4.18  11.7 ± 8.03  12.5 ± 5.97
  P-value * * NS NS 
C-peptide (ng/mg)
  Before  1.63 ± 0.33  2.00 ± 0.74  1.55 ± 0.86  2.65 ± 2.34
  After  1.99 ± 0.68  2.05 ± 0.99  1.95 ± 2.04  2.47 ± 1.09
  P-value * NS NS  NS 
Values  are  mean ± SD.
*p <0.05, ** p<0.01 by paired t-test between before and after treatment within group
§p<0.05  by  student  t-test  between  supplement  and  control  group
found in the higher HbA1c group after 4 weeks of supplementation. 
HbA1c  level changed from 8.57% to 8.30% and fasting glucose 
changed from 169.7 mg/dL to 150.7 mg/dL. Marginal changes 
of insulin and C-peptide were also shown in higher HbA1c. 
In order to figure out whether glycemic control indicators respond 
to the zinc supplementation differently by diabetic duration, we 
compared the changes of HbA1c, fasting glucose, insulin and 
C-peptide by the diabetic duration period as shown in Table 5. The 
fasting glucose was significantly reduced, after supplementation, 
among diabetics with less than 4 years of duration (Table 5). 
Meanwhile, insulin and C-peptide were significantly increased 
by supplementation in diabetics with more than 4 years of duration 
(p<0.001, p<0.05). Marginal improvement with supplementation 
was observed for HbA1c (p=0.076). The changes of glycemic control 
indicators after zinc supplementation was compared by plasma 
zinc levels of the subjects as presented in Table 6. When we 
compared the HbA1c, fasting plasma glucose, insulin and C-peptide 
between the two groups classified by baseline plasma level of 
zinc, significant changes in fasting blood glucose, insulin and 
C-peptide were observed for zinc supplemented diabetics with 
lower zinc status (p<0.05). 
Discussion
The Korean National Health and Nutrition Examination Survey 
indicated that the prevalence of diabetes mellitus has continuously 
increased in Korea (Ministry of Health & Welfare, 2006). 
Accordingly, public awareness on dietary practice to control the 
blood glucose level is growing, because maintaining the blood 
glucose in the normal range is essential to prevent or reduce 
the risk for diabetic complication (Kim et al., 1998; Franz et Hyun-Mee Oh and Jin-Sook Yoon 287
al., 2003). In this study, the average level of HbA1c for diabetic 
subjects (7.62%, 7.87%) were higher than normal range (5.0∼
6.0%), whereas that of normal subjects were 5.84% and 5.69. 
Fasting glucose level of diabetics were above normal range (70∼
120 mg/L). Both HbA1c and fasting glucose were significantly 
higher in diabetics than normal subjects (p<0.001). These results 
indicated that most of diabetic participants in this study were 
not under a tight glycemic control. Most of the diabetic subjects 
did not participate in a diabetic management program or visit 
doctors regularly. It seemed that they were not aware of the 
importance of dietary practice to control blood glucose level. 
Thus, inappropriate food choices might have resulted in the 
deterioration of zinc status. 
As hyperzincuria has been frequently reported among diabetics, 
which might be potential indications of zinc deficiency, zinc 
supplementation has been suggested to ameliorate the metabolic 
disturbance of diabetics (Salgueiro et al., 2001). Baseline levels 
of insulin and C-peptide in diabetic subjects were within normal 
range. Our study showed that serum insulin and C-peptide were 
significantly increased after zinc supplementation in patients with 
more than 4 years history of diabetics. Previous investigators have 
hypothesized that zinc enhances tyrosine kinase phosphorylation 
in the insulin signal transduction from in vitro studies (Simon 
& Taylor, 2000). However, it is hard to conclude from our results 
that the changes of insulin level following 4 weeks of 
supplementation reflect an improvement in insulin resistance. 
This is because we did not collect the data on insulin receptor 
and/or the changes of insulin-stimulated enzyme activities. 
In this study, marginal changes of blood glucose level 
(p=0.068) following supplementation was observed in diabetic 
subjects. An animal study showed that dietary zinc supplementation 
attenuated fasting hyperglycemia whereas a marginally Zn-deficient 
diet exacerbated fasting hyperglycemia in db/db mice (Simon & 
Taylor, 2001).
HbA1c concentration of diabetic patients did not change 
significantly after 4 weeks of zinc supplementation. Considering 
the fact that HbA1c reflects 2-3 months of glycemic control, our 
results are not unexpected. Our findings on the changes of HbA1c 
after 4 weeks of supplementation are consistent with the previous 
studies. It has been reported that zinc supplementation did not 
improve the level of HbA1c, while it was beneficial to maintaining 
immunity in type 2 patients (Niewoehner et al., 1986). Others 
also found that six months of zinc supplementation (=30 mg/day) 
did not modify the level of HbA1c nor glucose homeostasis 
significantly (Anderson et al., 2001; Roussel et al., 2003). 
When we attempted to compare the magnitude of the 
supplementation effects by the status of glycemic control or 
diabetic duration, we observed that more significant effects 
occurred in less controlled groups or those with a longer medical 
history of diabetes. Higher levels of HbA1c and fasting glucose 
with longer diabetic duration have been noted by other 
investigators (Rho & Ko, 1997). Therefore, we suggest that a 
short-term zinc supplementation may be effective on glycemic 
control for diabetic patients with higher HbA1c% concentration 
and shorter history of diabetes. 
Significant changes in fasting blood glucose, insulin and 
C-peptide were observed for zinc supplemented diabetics with 
lower zinc status (p<0.05) in our study. A recent randomized, 
clinical trial reported that 3 months of zinc supplementation (30 
mg/day) for type 2 diabetics may have beneficial effects in 
elevating serum zinc level, and improving their glycemic control 
as shown by decreasing their HbA1c% concentration (Al-Maroof 
& Al-Shabatti, 2006).
In summary, our study indicated that significant improvement 
of fasting glucose as well as HbA1c were observed in zinc 
supplemented diabetic patients with shorter diabetic duration, 
poorer glycemic control, and marginal zinc status. However, 
further investigation is needed before a firm conclusion could 
be drawn for the relationship between zinc supplementation and 
glycemic control. At present, more attention must be paid to 
improving the zinc status and glycemic control of Korean diabetic 
patients in order to prevent or minimize complications. 
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